On July 30, 2026, a Phase 1 clinical trial involving survodutide was listed with a status of recruiting. The study, registered as NCT07407348, is titled "A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body."
The trial is designed to compare how two different formulations of survodutide are taken up by the body in participants with overweight or obesity. It is currently in Phase 1 and is actively recruiting participants as of the listed date.
Survodutide remains an unapproved compound under research and is not authorized for general use outside of clinical study settings. No results, efficacy data, or safety outcomes have been posted for this trial as of the date noted.
This update reflects only the trial's registration status, phase, and stated purpose. No conclusions about the compound's effects, benefits, or risks can be drawn from this listing alone. Further updates may be reported as the trial progresses.
Readers can consult the compound overview page for additional background and context on survodutide.